Ipsen S.A. (IPSEY) Discusses Phase II LANTIC Data and Innovation in Engineered Neuroinhibitors for Aesthetic Indications Transcript
Ipsen S.A. recently discussed the Phase II LANTIC data related to their engineered neuroinhibitors aimed at aesthetic applications. The presentation highlighted the company's ongoing innovation in this field. Key executives participated in the call to provide insights and answer questions from analysts.
- ▪Ipsen S.A. is focusing on engineered neuroinhibitors for aesthetic indications.
- ▪The Phase II LANTIC data was a central topic during the recent conference call.
- ▪Key executives from Ipsen participated in the discussion, including the Executive VP and Head of R&D.
Seeking Alpha files mainly under finance. We currently carry 6,446 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906069-ipsen-s-a-ipsey-discusses-phase-ii-lantic-data-and-innovation-in-engineered-neuroinhibitors"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
